Press Releases

Press Releases

Dec 12, 2024
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Dec 10, 2024
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
Nov 12, 2024
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Nov 07, 2024
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Oct 23, 2024
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Oct 14, 2024
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Sep 30, 2024
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Sep 23, 2024
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Sep 13, 2024
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
Aug 28, 2024
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Displaying 1 - 10 of 27
Media & IR Contact
Investor Relations & Media Contact

Robin Garner
Investor Relations
Contact Us

Helpful Tools